Navigation Links
DISCOVERLIGHT BIOTIN ARRA from Pierce Biotechnology, Inc.

ProductsDISCOVERLIGHT BIOTIN ARRA from Pierce Biotechnology, Inc.
Company Pierce Biotechnology, Inc.
Item DISCOVERLIGHT BIOTIN ARRA
Price 
Description Each kit contains sufficient materials for 1,464 array sample elements.

Includes:
  • DiscoverLight Nitrocellulose Membrane: 4 each
  • Blocker BSA in PBS (10X): 50 ml
  • Streptavidin HRP-conjugated: 0.1 mg
  • BupH Phosphate Buffered Saline: 8 packs
  • 10% Tween-20: 2 x 10 ml ampules
  • SuperSignal West Pico Luminol Enhancer: 2 x 25 ml
  • SuperSignal West Pico Stable Peroxide: 2 x 25 ml
Info Pierce Biotechnology, Inc.Pierce Biotechnology, Inc.
Pierce Biotechnology, Inc.
3747 N. Meridian Rd.
P.O. Box 117
Rockford, IL 61105
Customer Service: 815-968-0747
Fax Number: 815-968-8148
Web Site: http://www.piercenet.com/
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. DISCOVERLIGHT RABBIT ARRA from Pierce Biotechnology, Inc.
2. DISCOVERLIGHT MOUSE ARRAY from Pierce Biotechnology, Inc.
3. DISCOVERLIGHT 6XHIS ARRAY from Pierce Biotechnology, Inc.
4. Modern Protein Chemistry: Practical Aspects from Pierce Biotechnology, Inc.
5. Protein-Protein Interactions, from Pierce Biotechnology, Inc.
6. Imject Freunds Complete Adjuvant (FCA) from Pierce Biotechnology, Inc.
7. Imject Freunds Incomplete Adjuvant (FIA) from Pierce Biotechnology, Inc.
8. Extracti-Gel D Detergent Removing Gel AffinityPak Columns from Pierce Biotechnology, Inc.
9. GUIDE TO PROTEIN PURIFICA from Pierce Biotechnology, Inc.
10. PROTEIN PROTOCOLS Book from Pierce Biotechnology, Inc.
11. Product Information Request - SuperSignal West Pico COMPLETE Biotinylated Protein Detection Kit from Pierce Biotechnology, Inc.
...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... The FRT-PGK-gb2-neo-FRT template is designed ... eukaryotic cells. The FRT-PGK-gb2-neo-FRT template encodes ... prokaryotic promoter (gb2) for expression of kanamycin ... eukaryotic promoter (PGK) for expression of neomycin ...
... is tailored to highly enrich ... of rat spleen cells. Cells ... (or compatible 0.5 Tesla) immunomagnetic ... CD4+ T cell content of ...
Biology Products:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology: